Ferroheme
- Generic Name
- Ferroheme
- Drug Type
- Small Molecule
- Chemical Formula
- C34H32FeN4O4
- CAS Number
- 14875-96-8
- Unique Ingredient Identifier
- 42VZT0U6YR
Guard Therapeutics' POINTER Study Reaches 25% Enrollment Milestone
• Guard Therapeutics has reached 25% enrollment in its Phase 2b POINTER study, evaluating RMC-035 for kidney protection during open-heart surgery.
• The POINTER trial is a randomized, double-blind, placebo-controlled study assessing RMC-035's impact on kidney function in approximately 160 patients.
• An independent Data Safety Monitoring Committee will conduct the first of two safety analyses in Q1 2025, remaining blinded to the company.
• The study's primary endpoint is the change in eGFR from baseline to 90 days post-surgery, with data expected approximately six months after enrollment completion.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath